ArticleEClinicalMedicine2024

Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.

Chao Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.